within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD06_Regdanvimab;

model Regdanvimab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.4259259259259256e-09,
    adminDuration = 600,
    adminMass = 4000 / 1000000,
    adminCount = 1,
    Vd = 0.0045,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0025,
    k12 = 5.405092592592593e-09,
    k21 = 5.405092592592593e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Regdanvimab</td></tr><tr><td>ATC code:</td><td>J06BD06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.296</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Regdanvimab is a recombinant human monoclonal antibody targeting the receptor binding domain of the SARS-CoV-2 spike protein. It is used for the treatment of mild-to-moderate COVID-19 in certain patients and has received emergency or conditional authorizations in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with COVID-19 following a single intravenous infusion.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J06BD06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Regdanvimab;
